Safety and efficacy of intratumoral injections of chimeric antigen receptor (CAR) T cells in metastatic breast cancer

Cancer Immunology Research

Volumn 5, Issue 12, 2017, Pages 1152-1161

  Tchou, Julia ^a,b   Zhao, Yangbing ^b   Levine, Bruce L ^b   Zhang, Paul J ^b   Davis, Megan M ^b   Melenhorst, Jan Joseph ^b   Kulikovskaya, Irina ^b   Brennan, Andrea L ^b   Liu, Xiaojun ^b   Lacey, Simon F ^b   Posey, Avery D ^a,b   Williams, Austin D ^a,b   So, Alycia ^a,b   Conejo Garcia, Jose R ^c   Plesa, Gabriela ^b   Young, Regina M ^b   McGettigan, Shannon ^b   Campbell, Jean ^d   Pierce, Robert H ^d   Matro, Jennifer M ^a,b   DeMichele, Angela M ^a,b   Clark, Amy S ^a,b   Cooper, Laurence J ^e   Schuchter, Lynn M ^a,b   Vonderheide, Robert H ^a,b   June, Carl H ^a,b   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; ELECTROLYTE; MESSENGER RNA; SCATTER FACTOR RECEPTOR; FUSION PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ALLERGIC REACTION; ANEMIA; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER TISSUE; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ELECTROLYTE BLOOD LEVEL; ELECTROPORATION; ERYTHEMA; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; HYPOTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MACROPHAGE; MALE; METASTATIC BREAST CANCER; MIDDLE AGED; MOUSE; MYALGIA; NAUSEA; NONHUMAN; RADIATION ENTEROPATHY; SIDE EFFECT; T LYMPHOCYTE; TUMOR GROWTH; TUMOR NECROSIS; TUMOR XENOGRAFT; URTICARIA; VOMITING; AGED; ANIMAL; BREAST TUMOR; CLINICAL TRIAL; CYTOTOXICITY; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOTHERAPY; MICE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85037606665     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-17-0189     Document Type: Article

References (28)

1. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365:725–33.
2. Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015; 7:303ra139.
3. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509–18.
4. Beatty GL, O'Hara M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps. Pharmacol Ther 2016;166:30–9.
5. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802–4.
6. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL. Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 1998;82:1513–20.
7. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008;68:4360–8.
8. Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006;12:6144–52.
9. Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, et al. Mono-valent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A 2013;110:E2987–96.
10. Perol M. Negative results of METLung study: an opportunity to better understand the role of MET pathway in advanced NSCLC. Transl Lung Cancer Res 2014;3:392–4.
11. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res 2014;2:112–20.
12. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res 2010;70:9053–61.
13. Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, et al. Phase 0 clinical trials: conceptions and misconceptions. Cancer J 2008;14:133–7.
14. Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, et al. Mesothelin, a novel immunotherapy target for triple negative breast cancer. Breast Cancer Res Treat 2012;133:799–804.
15. Li YR, Xian RR, Ziober A, Conejo-Garcia J, Perales-Puchalt A, June CH, et al. Mesothelin expression is associated with poor outcomes in breast cancer. Breast Cancer Res Treat 2014;147:675–84.
16. Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res 2015;3: 356–67.
17. Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009; 8:2221–31.
18. Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A 2009;106:3360–5.
19. Liu X, Jiang S, Fang C, Li H, Zhang X, Zhang F, et al. Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation. Protein Cell 2017;8:514–26.
20. Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016;6:664–79.
21. Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res 2015;17:52.
22. Ho-Yen CM, Green AR, Rakha EA, Brentnall AR, Ellis IO, Kermorgant S, et al. C-Met in invasive breast cancer: is there a relationship with the basal-like subtype? Cancer 2014;120:163–71.
23. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009;15:2207–14.
24. Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science 2005;309:264–8.
25. Foster AE, Leen AM, Lee T, Okamura T, Lu A, Vera J, et al. Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother 2007;30:506–16.
26. Corrales L, McWhirter SM, Dubensky TW, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest 2016;126:2404–11.
27. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia HHS public access. Sci Transl Med 2014;19: 224ra25.
28. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016;127:3321–30.